European NTM & Bronchiectasis Workshop
Vienna, 6–8 July 2019

Organised by
AFISM
Association Internationale pour la Promotion de Formations Spécialisées en Medicine et en Sciences Biologiques

Powered by
Publi Créations
Dear Colleagues and Partners,

We are glad to welcome you to the NTM & Bronchiectasis Workshop in Vienna!

Pulmonary nontuberculous mycobacterial disease and bronchiectasis are two hot topics in the recent literature. The diagnosis of pulmonary nontuberculous mycobacterial disease and the decision to treat must incorporate several clinical, microbiological, and radiographic features. Although guidelines have been published to aid the clinicians in making such decisions, the available evidences indicate that adherence to established guidelines is poor. An increase in NTM pulmonary and extra-pulmonary morbidity and mortality has been documented worldwide, especially among patients suffering from chronic respiratory diseases, including bronchiectasis, chronic obstructive pulmonary disease (COPD), or cystic fibrosis (CF), as well as among HIV-positive and other immunocompromised patients.

In the 10 years that have elapsed since the last multispecialty society guidelines were published, substantial work has been done by investigators worldwide in an attempt to answer key questions related to the epidemiology, prevention, diagnosis and treatment of NTM pulmonary disease. Despite the increased recognition of this group of microorganisms and the important role they play in chronic, pulmonary infectious diseases, there are crucial unanswered questions that remain.

The prevalence of bronchiectasis in the UK rose by 40% between 2004 and 2014, with similar increases noted worldwide. In September 2017, the European Respiratory Society published guidelines for adult bronchiectasis, which represent the first international standards of care for the disease following several national guidelines produced in the past decade. These guidelines show how far we still are from being able to deliver effective treatment in bronchiectasis.

Registries enrolling large numbers of patients are now reporting on patients from the United States and Europe and we have some insight into the disease in China as well. Our understanding of the microbiology of bronchiectasis is improving and important data have been published on the vicious cycle that relates inflammation and infection.

The role of macrolide therapy is being refined and the potential for new inhaled antibiotics exists. Which patients benefit from surgery is also been partially redefined.

Finally, collaborations between investigators in many parts of the world have yielded a better definition for a bronchiectasis exacerbation. The evolution of our understanding about this very heterogeneous disease is remarkable but we also await further translational studies and clinical trials to guide the care of individual patients.

There is a clear need for better education and improved knowledge of NTM pulmonary infection and bronchiectasis management.

The EUROPEAN NTM & BRONCHIECTASIS WORKSHOP (Vienna, July 6th – 8th, 2019), in the historical amazing framework of the Austrian capital, gives the opportunity to discuss and analyse the different diagnostic techniques, the role of new drugs and the optimal management of these two important diseases.

Wishing you a pleasant stay in Vienna and a fruitful and constructive Workshop

Your Sincerely

Stefano Aliberti
Associate Professor of Respiratory Medicine, University of Milan, Italy.
Consultant, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Co-chair of the European (EMBARC) and the Italian (IRIDE) Registry of adult bronchiectasis.
Chair of the Italian Registry on Non-Tuberculous Mycobacteria (IRENE).
Head of the Respiratory Infections Assembly, European Respiratory Society.

Francesco Blasi
Professor of Respiratory Medicine, Department of Pathophysiology and Transplantation, University of Milan, Italy.
Member of Board of Directors, University of Milan, Italy.
Head Internal Medicine Department, Respiratory Unit and Adult Cystic Fibrosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.
Co-chair of the Italian Registry of adult bronchiectasis (IRIDE).
Co-Chair of the Italian Registry of Non-Tuberculous Mycobacteria (IRENE).

James D. Chalmers
GSK/British Lung Foundation Professor of Respiratory Research and Honorary Consultant Respiratory Physician at the University of Dundee/Ninewells Hospital, Dundee.
Chair of the European Bronchiectasis Network (EMBARC).
Chair of the BTS Respiratory Infection Speciality Advisory Group.
Deputy chief editor of the European Respiratory Journal.
ORGANISING COMMITTEE

STEFANO ALIBERTI (Italy)
FRANCESCO BLASI (Italy)
JAMES D. CHALMERS (UK)

SCIENTIFIC COMMITTEE

KATERINA DIMAKOU (Greece)
PIETER C. GOEMINNE (Belgium)
CHARLES S. HAWORTH (UK)
MICHAEL LOEBINGER (UK)
ANTONI TORRES (Spain)
TOBIAS WELTE (Germany)

VENUE

IMPERIAL RIDING SCHOOL RENAISSANCE VIENNA HOTEL
Address: Ungargasse 60, 1030 Wien
T: +43 (0) 1 711 75 0

MEETING SPACES
PLENARY ROOM: Reitschule Room
Poster Sessions, Exhibition, Registration Desk and
Coffee Break: Foyer – Floor 1

ORGANISING SECRETARIAT

PUBLI CREATIONS
74 BD d’Italie, Monaco
MC, 98000 (Monaco)
Ph: +377 97 97 35 50
ntmbronchiectasis@publiccreations.com

www.ntmbronchiectasis.org
<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
</tr>
</thead>
<tbody>
<tr>
<td>F. Alhamed Alduihi</td>
<td>Syrian Arab Republic</td>
</tr>
<tr>
<td>S. Aliberti</td>
<td>Italy</td>
</tr>
<tr>
<td>C. Andrejak</td>
<td>France</td>
</tr>
<tr>
<td>F. Blasi</td>
<td>Italy</td>
</tr>
<tr>
<td>C. Castellani</td>
<td>Italy</td>
</tr>
<tr>
<td>J. D. Chalmers</td>
<td>UK</td>
</tr>
<tr>
<td>M. Clerici</td>
<td>Italy</td>
</tr>
<tr>
<td>L. Codecasa</td>
<td>Italy</td>
</tr>
<tr>
<td>A. De Soyza</td>
<td>UK</td>
</tr>
<tr>
<td>K. Dimakou</td>
<td>Greece</td>
</tr>
<tr>
<td>I. Eisenberg</td>
<td>Israel</td>
</tr>
<tr>
<td>S. Elborn</td>
<td>UK</td>
</tr>
<tr>
<td>R. A. Floto</td>
<td>UK</td>
</tr>
<tr>
<td>P.C. Goeminne</td>
<td>Belgium</td>
</tr>
<tr>
<td>D. E. Griffith</td>
<td>USA</td>
</tr>
<tr>
<td>T. Harm</td>
<td>The Netherlands</td>
</tr>
<tr>
<td>B. Harris</td>
<td>UK</td>
</tr>
<tr>
<td>C.S. Haworth</td>
<td>UK</td>
</tr>
<tr>
<td>A. Kantar</td>
<td>Italy</td>
</tr>
<tr>
<td>N. Jerjir</td>
<td>Belgium</td>
</tr>
<tr>
<td>M.R. Loebinger</td>
<td>UK</td>
</tr>
<tr>
<td>M. A. Martinez Garcia</td>
<td>Spain</td>
</tr>
<tr>
<td>E. Polverino</td>
<td>Spain</td>
</tr>
<tr>
<td>J. Quint</td>
<td>UK</td>
</tr>
<tr>
<td>D. Radovanovic</td>
<td>Italy</td>
</tr>
<tr>
<td>T. Ruddy</td>
<td>Germany</td>
</tr>
<tr>
<td>O. Sibila</td>
<td>Spain</td>
</tr>
<tr>
<td>P. Schenk</td>
<td>Austria</td>
</tr>
<tr>
<td>M. Shteinberg</td>
<td>Israel</td>
</tr>
<tr>
<td>P. Tarsia</td>
<td>Italy</td>
</tr>
<tr>
<td>J. Van Ingen</td>
<td>The Netherlands</td>
</tr>
</tbody>
</table>
### SATURDAY
**6 JULY 2019**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.00 - 14.00</td>
<td>Registration</td>
</tr>
<tr>
<td>14.00 - 14.15</td>
<td>Opening: Chairmen Introduction</td>
</tr>
<tr>
<td><strong>Session 1</strong></td>
<td>NTM – PD Epidemiology and Microbiology</td>
</tr>
<tr>
<td>14.15 - 15.30</td>
<td>Chair: F. Blasi (Italy)</td>
</tr>
<tr>
<td>14.45 - 15.15</td>
<td>J. Quint (UK)</td>
</tr>
<tr>
<td>14.45 - 15.15</td>
<td>NTM-PD: Microbiology – from standard microbiology to sequencing</td>
</tr>
<tr>
<td>15.15 - 15.30</td>
<td>J. Van Ingen (The Netherlands)</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>15.30 - 16.00</td>
<td>Coffee break</td>
</tr>
<tr>
<td><strong>Session 2</strong></td>
<td>NTM – PD: Diagnostics &amp; Treatments</td>
</tr>
<tr>
<td>16.00 - 17.15</td>
<td>Chairs: L. Codecasa (Italy), J. Van Ingen (The Netherlands)</td>
</tr>
<tr>
<td>16.00 - 16.30</td>
<td>NTM-PD: how can imaging help?</td>
</tr>
<tr>
<td>16.30 - 17.00</td>
<td>H. Tiddens (The Netherlands)</td>
</tr>
<tr>
<td>17.00 - 17.15</td>
<td>NTM-PD: who and when to treat?</td>
</tr>
<tr>
<td></td>
<td>M. R. Loebinger (UK)</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td><strong>Session 3</strong></td>
<td>Rising stars</td>
</tr>
<tr>
<td>17.15 - 18.15</td>
<td>Chairs: S. Aliberti (Italy), F. Blasi (Italy), J. D. Chalmers (UK), P. Schenk (Austria)</td>
</tr>
<tr>
<td>17.15 - 17.30</td>
<td>MARIO Warning Sign for Mortality in Acute Exacerbation of Bronchiectasis</td>
</tr>
<tr>
<td>17.45 - 18.00</td>
<td>Alhamed Aliduihi (Syrian Arab Republic)</td>
</tr>
<tr>
<td></td>
<td>Radiologic characteristics of non- Tuberculous mycobacteria infection in patients with bronchiectasis</td>
</tr>
<tr>
<td></td>
<td>I. Eisenberg (Israel)</td>
</tr>
<tr>
<td>18.15 - 19.00</td>
<td><strong>KEYNOTE LECTURE</strong></td>
</tr>
<tr>
<td></td>
<td>Chair: K. Dimakou (Greece)</td>
</tr>
<tr>
<td></td>
<td>NTM and Bronchiectasis: a new, old threat</td>
</tr>
<tr>
<td>18.45 - 19.00</td>
<td>C. S. Haworth (UK)</td>
</tr>
<tr>
<td></td>
<td>Discussion</td>
</tr>
<tr>
<td>Foyer – Floor 1</td>
<td>STROLLING POSTER SESSION 1 (for detailed sessions see from page 10 to page 15)</td>
</tr>
<tr>
<td>19.00 - 19.30</td>
<td>Welcome cocktail</td>
</tr>
</tbody>
</table>

Organised by: [AFISM](#)
### Session 4
08.30-09.00

**Patient point of view**
*Chair: M. Shteinberg (Israel)*

- How do I live with my NTM – PD
  *T. Ruddy (Germany)*

- How do I live with my Bronchiectasis
  *B. Harris (UK)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-08.45</td>
<td>How do I live with my NTM – PD</td>
<td>T. Ruddy (Germany)</td>
</tr>
<tr>
<td>08.45-09.00</td>
<td>How do I live with my Bronchiectasis</td>
<td>B. Harris (UK)</td>
</tr>
<tr>
<td>09.00-09.40</td>
<td>KEYNOTE LECTURE</td>
<td>R. A. Floto (UK)</td>
</tr>
<tr>
<td>09.30-09.40</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>09.40-10.20</td>
<td>KEYNOTE LECTURE</td>
<td>F. Blasi (Italy)</td>
</tr>
<tr>
<td>10.10-10.20</td>
<td>Discussion</td>
<td></td>
</tr>
<tr>
<td>10.20-10.50</td>
<td>Coffee break</td>
<td></td>
</tr>
</tbody>
</table>

### Session 5
10.50-11.55

**Bronchiectasis: Etiology and treatable traits**
*Chair: S. Elborn*

- Bronchiectasis – Idiopathic no more?
  *S. Aliberti (Italy)*

- Treatable and targetable traits in bronchiectasis
  *O. Sibila (Spain)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.50-11.15</td>
<td>Bronchiectasis – Idiopathic no more?</td>
<td>S. Aliberti (Italy)</td>
</tr>
<tr>
<td>11.15-11.40</td>
<td>Treatable and targetable traits in bronchiectasis</td>
<td>O. Sibila (Spain)</td>
</tr>
<tr>
<td>11.40-11.55</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Session 6
11.55-13.00

**Bronchiectasis: Cross – infections and deteriorating patient**
*Chair: M. A. Martinez Garcia (Spain)*

- Bronchiectasis: Is it possible to eradicate infections?
  *A. De Soyza (UK)*

- Bronchiectasis: The deteriorating patient
  *P.C. Goeminne (Belgium)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Chair/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.55-12.20</td>
<td>Bronchiectasis: Is it possible to eradicate infections?</td>
<td>A. De Soyza (UK)</td>
</tr>
<tr>
<td>12.20-12.45</td>
<td>Bronchiectasis: The deteriorating patient</td>
<td>P.C. Goeminne (Belgium)</td>
</tr>
<tr>
<td>12.45-13.00</td>
<td>Discussion</td>
<td></td>
</tr>
</tbody>
</table>

### Lunch
13.00-14.00

*Restaurant Borromeaus (Ground Floor)*
**SUNDAY 7 JULY 2019**

### Session 7

**14.00-15.15**
**NTM - PD: treatments**
**Chairs:** R. A. Floto (UK), C. S. Haworth (UK)

**14.00-14.30**
**MAC-PD: Antibiotics treatment regimens**
C. Andrejak (France)

**14.30-15.00**
**NON MAC-PD: Antibiotic treatment regimens**
J. Van Ingen (The Netherlands)

**15.00-15.15**
**Discussion**

### Session 8

**15.15-16.30**
**NTM-PD & Bronchiectasis: surgical options**
**Chair:** A. De Soyza (UK)

**15.15-15.45**
**Lung Immunology**
M. Clerici (Italy)

**15.45-16.15**
**Impact of NTM-PD on lung transplantation**
P. Tarsia (Italy)

**16.15-16.30**
**Discussion**

**16.30-17.00**
**Coffee break**

### KEYNOTE LECTURE

**17.00-17.45**
**Chair:** C. Castellani (Italy)
**Pediatric bronchiectasis: the dark side of the moon**
A. Kantar (Italy)

**17.30-17.45**
**Discussion**

### Radiology Masterclass: NTM and bronchiectasis on the stage

**17.45-19.00**
**Chair:** S. Aliberti (Italy)
**Clinical Cases Discussion**
H. Tiddens (The Netherlands) and N. Jerjir (Belgium)

### Foyer – Floor 1

**19.00 – 19.30**
**STROLLING POSTER SESSION 2** (for detailed sessions see from page 16 to page 21)
<table>
<thead>
<tr>
<th>Time</th>
<th>Keynote Lecture</th>
<th>Discussion</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30-09.15</td>
<td><strong>Keynote Lecture</strong>&lt;br&gt;Chair: F. Blasi (Italy)&lt;br&gt;Bronchiectasis Exacerbations: definition and significance&lt;br&gt; E. Polverino (Spain)</td>
<td></td>
</tr>
<tr>
<td>09.00-09.15</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>09.15-10.30</td>
<td><strong>Session 9</strong>&lt;br&gt;Bronchiectasis treatments&lt;br&gt;Chair: K. Dimakou (Greece)</td>
<td></td>
</tr>
<tr>
<td>09.15-09.45</td>
<td>Inhaled antibiotics treatments: any good news?&lt;br&gt;F. Blasi (Italy)</td>
<td></td>
</tr>
<tr>
<td>09.45-10.15</td>
<td>Macrolide and ICS: how to identify responders&lt;br&gt;J. D. Chalmers (UK)</td>
<td></td>
</tr>
<tr>
<td>10.15-10.30</td>
<td><strong>Discussion</strong></td>
<td></td>
</tr>
<tr>
<td>10.30-11.00</td>
<td><strong>Coffee break</strong></td>
<td></td>
</tr>
<tr>
<td>11.00-12.30</td>
<td><strong>Session 10</strong>&lt;br&gt;Difficult Clinical Cases&lt;br&gt;Chairs: S. Aliberti (Italy), F. Blasi (Italy), J. D. Chalmers (UK)&lt;br&gt;Discussants&lt;br&gt;F. Alhamed Alduihi (Syrian Arab Republic), I. Eisenberg (Israel), D. Radovanovic (Italy)</td>
<td></td>
</tr>
<tr>
<td>12.30-13.00</td>
<td><strong>Closing Remarks and Awards</strong></td>
<td></td>
</tr>
</tbody>
</table>
POSTER SESSIONS
SATURDAY, JULY 6, 2019 - Foyer - Floor 1

19:00 – 19:30
Strolling Poster Session 1 - Group 1
Cystic Fibrosis and Not-Cystic Fibrosis Bronchiectasis - Long term inhaled antibiotics
Moderators: James D. Chalmers (UK) - Michael Loebinger (UK)

1Erasmus Medical Centre, Rotterdam, Netherlands

Kseniia Suska1; Kateryna Gashynova1; Valeriia Dmytrychenko1
1State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Department of Occupational Diseases and Clinical Immunology, Dnipro, Ukraine

[1.1.3] Impact of Bronchiectasis on Post-operative Pulmonary Complications following Extra-pulmonary Surgery in Patients with Airflow Limitation.
Hayoung Choi1; Bumhee Yang2; Hye Yun Park3; Hyun Lee4
1Department of Internal Medicine, Hallym University College of Medicine, Chuncheon, Korea, South; 2Division of Pulmonology, Center of Lung Cancer, National Cancer Center, Goyang, Korea, South; 3Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Seoul, Korea, South; 4Department of Internal Medicine, Hanyang University College of Medicine, Seoul, Korea, South

[1.1.4] Inhaled ciprofloxacin (ARD-3150) in patients with non-cystic fibrosis bronchiectasis and frequent pulmonary exacerbations: a pooled analysis from ORBIT-3 and ORBIT-4.
James Chalmers1; Angela Davis2; Gregory Tino3; Igor Gonda4; Juergen Froehlich4
1Cambridge Centre for Lung Infection, Royal Papworth Hospital, Cambridge, United Kingdom; 2Grifols, Research Triangle Park, USA; 3Penn Presbyterian Medical Center, Pennsylvania, USA; 4Aradigm Corporation, Hayward, USA

[1.1.5] Lung pathophysiology over time in bronchiectasis: a three-year, longitudinal study.
Dejan Radovanovic1; Stefano Aliberti2; Andrea Gramegna3; Sebastian Ferri2; Angela Bellofiore2; Mariangela Retucci4; Alice Gelmini4; Carlotta di Francesco4; Alessandra Colombo4; Tommaso Pilocane1; Pierachille Santus1; Francesco Blasi4
1Division of Respiratory Diseases, Luigi Sacco University Hospital, Department of Biomedical and Clinical Sciences (DIBIC), University of Milan, Via G.B. Grassi 74, 20157, Milano, Italy; 2Department of Pathophysiology and Transplantation, University of Milan; Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Via Francesco Sforza 35, 20122, Milano, Italy

Organised by:
AFISM

European NTM & Bronchiectasis Workshop
Vienna, 6-8 July 2019
[1.1.6] Management of Australian adults with bronchiectasis in tertiary care - an analysis from the Australian Bronchiectasis Registry shows large gaps in care.
Simone Visser 1; Lucy Morgan2; ABC Australian Bronchiectasis Consortium3
1Royal Prince Alfred Hospital, Sydney, Australia; 2Concord Repatriation General Hospital, Sydney, Australia; 3Lung Foundation Australian, Brisbane, Australia

Victoria Contreras-Bolivar1; Guillermo Bentabol-Ramos2; Casilda Olveira2; Eva Acosta2; José Abuín-Fernández3; Eva García-Escobar1; Gabriel Olveira1
1Endocrinology And Nutrition. Hospital Regional Universitario, Málaga, Spain; 2Pneumology. Hospital Regional Universitario, Málaga, Spain

[1.1.8] Severe Uncontrolled Asthma with Non-Cystic Fibrosis Bronchiectasis: What is treatment option for such patients?
Alizaman Sadigov1
1Azerbaijan Medical University, Baku, Azerbaijan

[1.1.9] The lower airway microbiome in patients with bronchiectasis due to primary ciliary dyskinesia (PCD) is unique.
Lucy Morgan1; Steven Taylor2; Cameron Stevens1; Simone Visser3; Geraint Rogers2
1Department of Respiratory Medicine, Concord Hospital Clinical School, Sydney, Australia; 2SAHMRI Microbiome Research Laboratory, College of Medicine and Public Health, Flinders University, Adelaide, Australia; 3Department of Respiratory Medicine, RPA Clinical School, Sydney, Australia
[1.2.1] A new genetic diagnosis of Primary Ciliary Dyskinesia in three patients with idiopathic bronchiectasis.
Adi Dagan1; Amir Onn1; Ori Efrati1
1Pulmonary Institute, Sheba Medical Center, Affiliated to Tel Aviv University, Ramat Gan, Israel

[1.2.2] Allergic bronchopulmonary aspergillosis bronchiectasis: radiological and microbiological profile of patients presented in outpatient pulmonary clinic of a tertiary care hospital of Karachi, Pakistan.
Nousheen Iqbal1,2; Muhammad Irfan2; Kausar Jabeen2
1Jinnah Medical and dental college Karachi, Karachi, Pakistan; 2Aga Khan University Hospital, Karachi, Pakistan

[1.2.3] Assessment of the exercise capacity and its correlation with the prognosis of the bronchiectasis.
Sindy Cedeño de Jesús1; Virginia Almadana Pacheco2; Agustin Valido Morales3; Rut Ayerbe2; Ana Miriam Muñiz Rodriguez2
1Infanta Elena Hospital, Sevilla, Spain; 2University Hospital Virgen Macarena, Sevilla, Spain; 3Respiratory Rehabilitation Unit, Sevilla, Spain

[1.2.4] Genetic variation in innate immune receptors influences susceptibility to bacterial infection in patients with bronchiectasis.
Cláudio Duarte-Oliveira1,2; Cristina Cunha1,2; Margarida Redondo5; Adelina Amorim3,5; Luciana Oliveira5; Natália Martins1,4,5; Agostinho Carvalho1,2
1Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal; 2ICVS/3B’s - PT Government Associate Laboratory, University of Minho, Braga/Guimarães, Portugal; 3Faculty of Medicine, Porto, Portugal; 4Institute for Research and Innovation in Health (i3S), Porto, Portugal; 5Pulmonology Department, Centro Hospitalar de S. João, Porto, Portugal

[1.2.5] Genome-wide association study in patients with pulmonary Mycobacterium avium complex disease.
Ho Namkoong1,2; Omae Yosuke3; Asakura Takanori2,4; Yoshida Mitsunori4; Suzuki Shoji2; Morimoto Kozo5; Oler Andrew1; Szymanski Eva1; Matsuda Shuichi5; Yagi Kazuma2; Ishii Makoto2; Hase Isano5; Nishimura Tomoyasu2; Sasaki Yuka6; Asami Takahiro2; Shiomori Tetsuya2; Matsubara Hiroaki8; Shimada Hisato9; Ato Manabu4; Kosaki Kenjiro2; Betsuyaku Tomoko2; Kurashima Atsuyuki3; Tettelin Hervé30; Olivier Kenneth1;
Hoshino Yoshihiko4; Steven Holland1; Tokunaga Katsushi3; Hasegawa Naoki2
1NIH, Maryland, USA; 2Keio University School of Medicine, Tokyo, Japan; 3The University of Tokyo, Tokyo, Japan; 4National Institute of Infectious Diseases, Tokyo, Japan; 5Japan Anti-Tuberculosis Association, Tokyo, Japan; 6National Hospital Organization Utsunomiya Hospital, Tochigi, Japan; 7Keiyu Hospital, Kanagawa, Japan; 8Fussa Hospital, Tokyo, Japan; 9Kawasaki Municipal Ida Hospital, Kanagawa, Japan; 10University of Maryland, Maryland, USA

Iffat Khanum1; Nousheen Iqbal1
1Aga Khan University Hospital, Karachi, Pakistan

[1.2.7] Physical activity and submaximal exercise capacity in patients with bronchiectasis.
Sindy Cedeño de Jesús1
1Infanta Elena Hospital, Huelva, Spain; 2Virgen Macarena University Hospital, Seville, Spain; 3Respiratory Rehabilitation Unit, Seville, Spain

[1.2.8] Staphylococcus aureus versus Pseudomonas aeruginosa in sputum of bronchiectasis patients: a molecular biology evaluation.
Leonardo Terranova1; Martina Oriano1,2,3; Andrea Gramena1,2; Camilla Tafuro1; Carlotta Di Francescos1,2; Alice Gelmini1,2; Francesca Grande1,3; Martina Ghiorzo1,3; Luca Ruggiero1,4; Paola Marchisio1,4; Stefano Aliberti1,2; Francesco Blasi1,2
1Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Internal Medicine Department, Respiratory unit and Adult Cystic Fibrosis Center, Milan, Italy; 2University of Milan, Department of Pathophysiology and Transplantation, Milan, Italy; 3Department of Molecular Medicine, University of Pavia, Pavia, Italy; 4Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Paediatric Highly Intensive Care Unit, Milan, Italy; 5University of Piemonte Orientale, Department of Health Sciences, Novara, Italy

Guillermo Bentabol-Ramos1; Alicia Padilla-Galo2; Mª Victoria Girón-Fernández3; Rosa Girón4; Carmen Villal4,5; Yadira Dobarganes4,5; Luis Maiz4; Marta García-Clemente2; Oriol Sibila2; Rafael Golpe5; Juan Rodríguez3; Esther Barreiro3; Juan Luis Rodríguez2,5; Rosario Menéndez4; Concepción Prados4; David de la Rosa15; Miguel Ángel Martínez-García15; Casilda Olveira2,16
1Servicio de Neumología, Hospital Regional Universitario, Málaga, Spain; 2Unidad de Neumología, Hospital Costa del Sol, Marbella, Málaga, Spain; 3Servicio de Neumología, Hospital Universitario de la Princesa, Madrid, Spain; 4Servicio de Neumología, Clínica Puerta de Hierros, Madrid, Spain; 5Servicio de Neumología, Clínica Ibermedic, Madrid, Spain; 6Unidad de Bronquitectasías y Fibrosis Quística, Hospital Universitario Ramón y Cajal, Madrid, Spain; 7Servicio de Neumología, Hospital Universitario Central de Asturias, Oviedo, Spain; 8Servicio de Neumología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 9Servicio de Neumología, Hospital Universitario Lucus Augusti, Lugo, Spain; 10Servicio de Neumología, Hospital San Agustín de Avilés, Avilés, Asturias, Spain; 11Pulmonology Department, Muscle Wasting Research Group, Hospital del Mar-MIM, CEXS, UPF, CIBERES, Barcelona, Spain; 12Servicio de Neumología, Hospital Clínico San Carlos, Madrid, Spain; 13Servicio de Neumología, Hospital Universitari Gregorio Marañón, Madrid, Spain; 14Servicio de Neumología, Hospital Universitario La Fe, Valencia, Spain; 15Servicio de Neumología, Hospital Universitario La Paz, Madrid, Spain; 16Unidad de Neumología, Hospital Plató, Barcelona, Spain; 17Instituto de Biomedicina de Málaga (IBIMA), Málaga, Spain
[1.3.1] A five years’ service evaluation of a paediatric rapid response community respiratory physiotherapy service.
Posso Claudia¹; Stephens Alice¹
¹Royal London Hospital, London, United Kingdom

[1.3.2] C-reactive protein concentration in steady-state bronchiectasis: prognostic value of future hospitalizations. Data from the Spanish Registry of Bronchiectasis (RIBRON).
Tomás Posadas¹; Grace Oscullo¹; Carmen Villa²; Yadira Dobarganes²; Rosa Girón³; Casilda Olveira³; Luis Maíz³; Marta García-Clemente⁴; Oriol Sibila⁵; Rafael Golpe⁶; Juan Rodríguez⁷; Ester Barreiro⁸; Juan-Luis Rodriguez⁹; Rosario Menéndez⁹; Concepción Prados¹⁰; David de la Rosa Carrillo¹⁰; Miguel-Ángel Martínez-García¹
¹Hospital Universitario y Politécnico de La Fe, Valencia, Spain; ²Clinica Fuensanta, Madrid, Spain; ³Hospital La Princesa, Madrid, Spain; ⁴Hospital Regional de Málaga, Málaga, Spain; ⁵Hospital Ramón y Cajal, Madrid, Spain; ⁶Hospital Central de Asturias, Oviedo, Spain; ⁷Hospital Santa Creu i Sant Pau, Barcelona, Spain; ⁸Hospital Lucus Augusti, Lugo, Spain; ⁹Hospital San Agustin, Avilés, Spain; ¹⁰Hospital del Mar, Barcelona, Spain; ¹¹Hospital Clínico San Carlos, Madrid, Spain; ¹²Hospital La Paz, Madrid, Spain; ¹³Hospital Plató, Barcelona, Spain

[1.3.3] If the inhalation of hypertensive sodium chloride in combination with hyaluronic acid is effective in patients with non-cystic fibrosis bronchiectasis?
Tetyana Pertseva¹; Kateryna Gashynova²; Kseniia Suska²; Valeriia Dmytrychenko²
¹State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Department of Internal Medicine #1, Dnipro, Ukraine; ²State Institution “Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine”, Department of Occupational Diseases and Clinical Immunology, Dnipro, Ukraine

[1.3.4] Inhaled antibiotics for non-cystic fibrosis patients with chronic bronchial infection by non-Pseudomonas microorganisms.
Rui Ribeiro¹; José Miguel Lobato¹; Marli Ferreira¹; Andrea Mateus¹; João Neves¹
¹Internal Medicine Department, Centro Hospitalar Universitário do Porto, Porto, Portugal
[1.3.5] New instruments for stable treatment of patients with chronic obstructive pulmonary disease and bronchiectasis.
Vladimir Antonov¹; Galina Ignatova¹
¹South Ural State Medical University, Chelyabinsk, Russian Federation

[1.3.6] Sputum metabolites correlate with neutrophilic inflammation in bronchiectasis.
Ashley Giam¹; Amelia Shoemark¹; Holly Keir¹; Simon Finch¹; Lidia Perea²; Oriol Sibila²; Stefano Aliberti³; James D Chalmers¹
¹University of Dundee (UK), ²Hospital Sant Pau - Barcelona (Spain), ³University of Milan - Milan (Italy)

Iffat Khanum¹
¹Aga Khan University Hospital, Karachi, Pakistan

[1.3.8] The transcriptomic stress response of M. avium and M. abscessus indicates possible cross-resistance following low-level antibiotic exposure.
Jodie Schildkraut¹; Jordy Coolen¹; Jakko van Ingen¹
¹Department of Medical Microbiology & Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, Netherlands
Huiye Michelle Lee; Cheryl Khoong; Yixuan Dorothy Lim; Soon Keng Goh; Monica Chan; Akash Verma; Abisheganaden John; Yick Hou Albert Lim
1Department of Respiratory and Critical Care Medicine, Tan Tock Seng Hospital, Singapore, Singapore; 2Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore; 3Department of Infectious Diseases, Singapore, Singapore

[2.1.2] Characteristic of 42 patients with positive respiratory culture in Mycobacterium abscessus.
Daniel Laorden Escudero; Pablo Mariscal Aguilar; Andrés Giménez Velando; Sarai Quirós Fernández; Carlos Javier Carpio Segura; Concepción Prados Sánchez; Rodolfo Álvarez-Sala Walther; Rosa Girón Moreno; Carlos Toro Rueda
1Department of Respiratory Medicine University Hospital La Paz, Madrid, Spain; 2Department of Respiratory Medicine University Hospital Fundación Jiménez Díaz, Madrid, Spain; 3Department of Respiratory University Hospital La Princesa, Madrid, Spain; 4Department of Microbiology University Hospital La Paz, Madrid, Spain

[2.1.3] Characteristics of patients with bronchiectasis and pulmonary non-tuberculous Mycobacterial infection: Data from a Greek cohort.
Maria Kaponi; Sofia Koukidou; Ourania Papaioannou; Apostolos Papavasileiou; Anna Gousiou; Theodoros Karampitsakos; Georgios Hillas; Katerina Dimakou
115th Respiratory Department, “Sotiria” Chest Hospital, Athens, Greece; 2National Center of Tuberculosis, “Sotiria” Chest Hospital, Athens, Greece; 3American College of Greece, Deree, Athens, Greece

[2.1.4] Clinical and immunological profile of patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis.
Sanne MH Zweijpfenning; Milou MF Schuurbiers; Mariolina Bruno; Cecile Magis–Escurra; Martin J Boeree; MG Netea; Jakko Van Ingen; Frank van de Veerdonk; Wouter Hoefsloot
1Radboudumc, Nijmegen, Netherlands
[2.1.5] Experience of treatment of Mycobacterium abscessus pulmonary disease with the presence of inducible clarithromycin resistance in a regional hospital in Hong Kong with genomic analysis of the mycobacterial strains.
Wai On Tam¹; Chi Fong Wong²; Teresa KF Wang²; Chi Wai Yip³; Ka Lun Tsang³
¹TB and Chest Unit, Grantham Hospital, Hong Kong, Hong Kong (China); ²Department of Pathology, Tuen Mun Hospital, Hong Kong, Hong Kong (China); ³Microbiology Division, Public Health Laboratory Services Branch, Centre for Health Protection, Department of Health, Hong Kong, Hong Kong (China)

[2.1.6] Mycobacterium abscessus pulmonary infection: is the treatment possible?
Joao Costeira¹²; Paula Esteves¹; Conceicao Gomes²; Cristina Barbara¹
¹Centro Hospitalar Universitário de Lisboa Norte, Departamento de Pneumologia, Lisbon, Portugal, Lisboa, Portugal; ²Centro de Diagnóstico Pneumológico Dr Ribeiro Sanches, Lisboa, Portugal, Lisboa, Portugal

Carlo Castellani¹; Federico Cresta¹; Gaia Cipresso¹; Luca Arcuri¹; Rosaria Casciaro¹; Silvia Garuti¹
¹IRCCS Giannina Gaslini Institute, Cystic Fibrosis Center, Genova, Italy

[2.1.8] Synergy between ethambutol and rifampicin or clarithromycin is not correlated to therapy failure in patients with MAC-PD.
Sanne M.H. Zweijpfenning¹; Lian J. Pennings¹; Marielle Rockland¹; Martin J. Boere¹; Wouter Hofsloot¹; Jakko van Ingen¹
¹Radboudumc, Nijmegen, Netherlands
19:00 – 19:30
Strolling Poster Session 2 – Group 2
Definition / Diagnosis of NTM – PD – Patients’ follow up
Moderators: Stefano Aliberti (Italy) – Anthony De Soyza (UK)

David de la Rosa Carrillo1; Casilda Oveira Fuster2; Marta García-Clemente3; Rosa María Girón Moreno4; Rosa Nieto Royo5; Annie Navarro Rolon6; Concepción Prados Sánchez7; Oriol Síbila8; Miguel-Ángel Martínez-García9
1Pneumology Service, Hospital Plató, Barcelona, Spain; 2Pneumology Service, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga/Universidad de Málaga, Málaga, Spain; 3Pneumology Service, Hospital Universitario Central de Asturias, Oviedo, Spain; 4Pneumology Service, Hospital de la Princesa, Madrid, Spain; 5Pneumology Service, Hospital Universitario Ramón y Cajal, Madrid, Spain; 6Pneumology Service, Hospital Mutua de Terrassa, Terrassa, Spain; 7Pneumology Service, Hospital Universitario La Paz-IS Carlos III, Madrid, Spain; 8Pneumology Service, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; 9Pneumology Service, Hospital Universitario y Politécnico de La Fe, Valencia, Spain

[2.2.2] Clinical relevance of differentiation between M. avium and M. intracellulare in M. avium complex pulmonary disease.
Goran Glodić1; Sanja Popović Grle1,7; Miroslav Samaržija1,7; Ante Marušić1; Dražen Strelec2; Ljiljana Žmak6; Vesna Carević Vladić6; Kristina Lalić3; Martina Dokoza4; Mateja Janković Makek1,7
1University Hospital Centre Zagreb, Zagreb, Croatia; 2Hospital for Pulmonary Diseases and TBC Klenovnik, Klenovnik, Croatia; 3Clinical hospital Dubrava, Zagreb, Croatia; 4Zadar General Hospital, Zadar, Croatia; 5General Hospital Dubrovnik, Dubrovnik, Croatia; 6National Tuberculosis Reference Laboratory, Croatian National Institute of Public Health, Zagreb, Croatia; 7University of Zagreb, School of Medicine, Zagreb, Croatia

Irene Latorre1,2,3; Raquel Villar-Hernández1,2,3; Zoran Stojanovic2,4; Beatriz Muriel-Moreno1,2,3; Antoni Noguera-Julian5,6; Maria Cols-Roig5; Marisol Domínguez8; Alicia Marín2,4; Maria Luiza de Souza-Galва9; Yolanda Galea10; Josefin Sabriá11; Cristina Prat1,2,3; Jordi B Torrentes12; Jose Domínguez1,2,3
1Servei de Microbiología. Hospital Universitari Germans Trias i Pujol, Institut d'Investigació Germans Trias i Pujol, Badalona, Spain; 2CIBER Enfermedades Respiratorias, CIBERES, Instituto de Salud Carlos III, Madrid, Spain; 3Univerrsitat Autònoma de Barcelona, Barcelona, Spain; 4Servei de Pneumologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain; 5Malalties Infeccioses i Resposta Inflamatòria Sistèmica en Pediatría, Unitat d’Infeccions, Servei de Pediatria, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain; 6CIBER de Epidemiología y Salud Pública, CIBERESP, Madrid, Spain; 7Unidad de Pneumología Pediátrica, Servei de Pediatria: Hospital Sant Joan de Déu, Barcelona, Spain; 8Servei de Pneumologia, Hospital del Mar, Barcelona, Spain.
[2.2.4] FEV1 evolution in a cohort of patients with bronchiectasis.
Margarida Redondo1; David Araújo1; Natália Martins1,2,3; Adelina Amorim1
1Centro Hospitalar Universitário de São João, Porto, Portugal; 2Faculty of Medicine, University of Porto, Portugal; 3Institute for Research and Innovation in Health, Portugal

[2.2.5] MARIO Warning Sign for Mortality in Acute Exacerbation of Bronchiectasis.
Fatima Alhamed Alduihi1; Khoury Abdulla2
1Resident doctor, Aleppo, Syrian Arab Republic; 2Prof, Aleppo, Syrian Arab Republic

[2.2.6] Psychometric validation of the EQ-5D-3L in Patients with Nontuberculous Mycobacterial Lung Disease Caused by Mycobacterium Avium Complex.
Anuj Shah1; Xinyi Ng1; Ruchit Shah1; Caitlyn Solem1; Ping Wang2; Marko Obradovic3
1Pharmerit International, Bethesda, USA; 2Insmed Incorporated, Bridgewater, USA; 3Insmed Germany, Frankfurt, Germany

[2.2.7] Pulmonary non-tuberculous mycobacterial infection in immunocompetent host misdiagnosed as tuberculosis: a case series.
Nousheen Iqbal1,2; Iffat Khanum2; Bizanjo Mahwash1; Riaz Urooj1; M Sajjad Sarwar2; Irfan Muhammad2
1Jinnah Medical and Dental college, Karachi, Pakistan; 2Aga Khan University Hospital, Karachi, Pakistan; 3Bahawal Victoria Hospital, Bahawalpur, Punjab, Pakistan

[2.2.8] Pulmonary NTM disease treated as Pulmonary TB: an interesting case report of an Indian Female.
Enrica Intini1; Zarir F Udwadia2; Luca Richeldi1
1Division of Respiratory Medicine, A. Gemelli University Hospital, Catholic University of the Sacred Heart, Rome, Italy; 2Department of Respiratory Medicine, P.D. Hinduja National Hospital and MRC, Mumbai, Maharashtra, India

[2.2.9] Treatment outcomes in patients with nontuberculous mycobacterial pulmonary disease in Croatia.
Goran Glodić1; Ljiljana Žmak1; Miroslav Samaržija1,3; Ana Marija Solaj1; Ante Marušić1; Ivana Mareković1,3; Feđa Džubur1,3; Ana Hećimović1; Andrea Vukić Dugac1,3; Dina Miheliči1; Marko Jakopović1,3; Gzim Redžepi1; Brigita Tičić1; Ljiljana Kardum Bulat1,3; Sanja Popović Grle1,3; Blaženka Barišić1; Jakko Van Ingen1; Mateja Janković Makek1,3
1University Hospital Center Zagreb, Zagreb, Croatia; 2National Mycobacteria Reference Laboratory, Croatian Institute of Public Health, Zagreb, Croatia; 3University of Zagreb, School of Medicine, Zagreb, Croatia; 4University of Rijeka, School of Medicine, Rijeka, Croatia; 5Clinical Hospital Center Rijeka, Rijeka, Croatia; 6Radboud University Medical Centre (Radboudumc), Nijmegen, Netherlands; 7Special hospital for Lung Diseases, Zagreb, Croatia
[2.3.1] Comorbid bronchiectasis is associated with increased mortality in patients with corticosteroid-dependent asthma.
Hyun Lee\textsuperscript{1}; Chung Sung Jun\textsuperscript{1}; Yeo Yoomi\textsuperscript{1}; Park Dong Won\textsuperscript{1}; Park Tai Sun\textsuperscript{1}; Moon Ji-Yong\textsuperscript{1}; Kim Tae-Hyung\textsuperscript{1}; Sohn Jang Won\textsuperscript{1}; Yoon Ho Joo\textsuperscript{1}; Kim Sang-Heon\textsuperscript{1}
\textsuperscript{1}Hanyang University, Seoul, Korea, South

David de la Rosa Carrillo\textsuperscript{1}; Annie Navarro Rolon\textsuperscript{2}; Marc Miravitlles\textsuperscript{3}; Antonia Ocaña Padilla\textsuperscript{4}; Pilar Martínez Olondriz\textsuperscript{5}; Miguel-Angel Martinez-Garcia\textsuperscript{6}
\textsuperscript{1}Pneumology Service, Hospital Plató, Barcelona, Spain; \textsuperscript{2}Pneumology Service, Hospital Mutua de Terrassa, Barcelona, Spain; \textsuperscript{3}Pneumology Service, Hospital Vall’Hebron, Barcelona, Spain; \textsuperscript{4}Centro de Atención Primaria Ocata-Teià, Barcelona, Spain; \textsuperscript{5}Pneumology Service, Hospital Universitario y Politècnico de La Fe, Valencia, Spain

[2.3.3] Differences in burden of disease and management practices for bronchiectasis across 5 EU countries: Data from the EMBARC registry.
J.D. Chalmers\textsuperscript{1}; S. Aliberti\textsuperscript{2}; R. Menendez\textsuperscript{2}; F. Ringshausen\textsuperscript{4}; A. De Soyza\textsuperscript{5}; M. Vendrell\textsuperscript{6}; E. Polverino\textsuperscript{6}; W. Boersma\textsuperscript{7}; C. Haworth\textsuperscript{8}; K. Dimakou\textsuperscript{9}; A.T. Hill\textsuperscript{10}; M.R. Loebinger\textsuperscript{11}; J.S. Elborn\textsuperscript{12}; P.C. Goeminne\textsuperscript{13}; F. Blasi\textsuperscript{14}
\textsuperscript{1}University of Dundee (UK), \textsuperscript{2}University of Milan (Italy), \textsuperscript{3}Hospital La Fe, Valencia (Spain), \textsuperscript{4}Hannover Medical School – Hannover (Germany), \textsuperscript{5}Freeman Hospital, Newcastle (UK), \textsuperscript{6}Barcelona, \textsuperscript{7}Alkmaar Hospital (The Netherlands), \textsuperscript{8}Papworth Hospital Cambridge (UK), \textsuperscript{9}Sotiria Chest Hospital, Athens (Greece), \textsuperscript{10}Edinburgh Royal Infirmary (UK), \textsuperscript{11}Brompton Hospital, London (UK), \textsuperscript{12}Hospital Clinic Barcelona (Spain), \textsuperscript{13}Queens University, Belfast (Ireland), \textsuperscript{14}AZ Nikolaas (Belgium)

JA Schildkraut\textsuperscript{3}; J Overbeek\textsuperscript{4}; M Bakker\textsuperscript{4}; W Hoefsloot\textsuperscript{3}; J van Ingen\textsuperscript{3}; R Van der Laan\textsuperscript{1}; M Obradovic\textsuperscript{2}
\textsuperscript{1}Insmed, Utrecht, Netherlands; \textsuperscript{2}Insmed, Frankfurt, Germany; \textsuperscript{3}Radboud University Medical Centre, Nijmegen, Netherlands; \textsuperscript{4}PHARMO Institute, Utrecht, Netherlands
[2.3.5] Identification of potentially undiagnosed patients with non-tuberculous mycobacterial lung disease using machine learning applied to primary care data in UK.
Orla Doyle¹; Peter McMahon¹; Flora Daniels¹; Ashley Pitcher²; Marko Obradovic³; Roald Van der Laan⁴; Michael Loebinger⁵
¹IQVIA, London, United Kingdom; ²IQVIA, Copenhagen, Denmark; ³Insmed Germany, Frankfurt, Germany; ⁴Insmed Netherlands, Utrecht, Netherlands; ⁵Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom

[2.3.6] Importance in the existence of bronchiectasias in the patient with chronic obstructive pulmonary disease.
Esperanza Salcedo Lobera¹; Guillermo Bentabol Ramos¹
¹Hospital Regional Universitario de Málaga, Málaga, Spain

[2.3.7] Is Pseudomonas aeruginosa a problem in patients with bronchiectasis in Dnipro region of Ukraine?
Tetyana Pertseva¹; Kateryna Gashynova²; Tetyana Kirieieva¹; Victoriia Rodionova²; Valeriia Dmytrychenko²; Kseniia Suska²; Kateryna Bogatska¹
¹State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Department of Internal Medicine #1, Dnipro, Ukraine; ²State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Department of Occupational Diseases and Clinical Immunology, Dnipro, Ukraine

[2.3.8] Predisposing factors for more severe bronchiectasis in adults.
Kseniia Suska¹; Kateryna Gashynova¹; Valeriia Dmytrychenko¹
¹State Institution "Dnipropetrovsk Medical Academy of the Ministry of Health of Ukraine", Department of Occupational Diseases and Clinical Immunology, Dnipro, Ukraine

Cecilia Burattini¹; Valentina Conio¹; Rita Di Domenica¹; Alessandro Cascina¹; Claudio Valizia¹; Domenica Di Costanzo¹; Laura Saracino¹; Federica Albicini¹; Amelia Grosso¹; Erica Gini¹; Isa Cerveri¹; Angelo Guido Corsico¹
¹Division of Respiratory Diseases, IRCCS Policlinico San Matteo Foundation, Department of Internal Medicine and Therapeutics, University of Pavia, PAVIA, Italy
GENERAL INFORMATION

SECRETARIAT DESKS
The secretariat desk opens on Saturday, July 6th from 12.00 (noon) and it’s open as follow:
• July 6th: 12.00 – 8.30 pm (end of the Welcome Ceremony)
• July 7th: 08.00 am – 7.30 pm
• July 8th: 08.00 am – 2.00 pm (end of the Workshop)

ADMISSION
A copy of the participants’ badge has been mailed to all the confirmed attendees. Please remind to print out your badge in A4 format and always bring it with you during the Workshop days. NO badges distribution is made on site. The Organizing Secretariat provides to participants necklace and badge holder.
Only badge holders will be admitted to the appropriate sessions, exhibition and social events.

PRESENCE CONTROL
Effective attendance is checked through badge scanning when going in and coming out of the plenary room. A minimum of 6 hours of effective attendance is required to issue the certificate of attendance.

CERTIFICATE OF ATTENDANCE
The certificate of attendance will be downloadable from the website www.ntmbronchiectasis.org using your personal credentials sent by e-mail, starting from July 12th, 2019.

Important note: Certificate of attendance would be delivered only to registered participants who attend at least 6 hours of congress sessions.

EUROPEAN ACCREDITATION
The European NTM & Bronchiectasis Workshop, has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 16 European CME credits (ECMEC®) covering the whole programme.

EBAP (European Board for Accreditation in Pneumology) has granted 15 CME Credits covering the whole programme.

INSURANCE
The Congress Organisers cannot accept liability for personal injuries sustained, or for loss or damage to property belonging to Congress participants, either during or as a result of the Congress. Registration does not include insurance. It is strongly recommended that you take an insurance policy of your choice as you register for the Congress and book your travel.

LANGUAGE
The official language of the Congress is English. No simultaneous translation will be provided.

WIFI
FREE Wifi is available in the meeting spaces and in the exhibition area.
Please select the network: Renaissance_Conference
Password: NTM2019
THE WORKSHOP APP

- Go to the right store
- Search for **NTM2019**
- Once you’ve found the app, tap either Download or Install

Please note that the APP is your main tool for the scientific programme, information and news related to the Workshop

A green choice of the European NTM & Bronchiectasis Workshop
ACKNOWLEDGEMENTS

The Scientific Committee thanks the sponsors and exhibitors of the European NTM & Bronchiectasis Workshop, for the unconditioned and unrestricted support to the initiative:

PLATINUM SPONSOR

IN COOPERATION WITH

VIENNA
CONVENTION BUREAU
The European NTM & Bronchiectasis Workshop will be recorded and broadcasted on

http://www.ntmbronchiectasis.org/

from July 30th, 2019

Would you like to have additional occasions to update and follow up after the Workshop?

DON’T MISS THE AFTER WORKSHOP NEWSLETTER TO KNOW MORE

NO PROBLEM!